Loading…
Loading…
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership. Volatility and Risk Relmada Therapeutics has a
ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by 1,364.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 451,918 shares of the company's stock after acquiring an additional 421,052 shares during the period. ADAR1 Capital Management LLC owned approximately 0.43%
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa.
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 10,647,441 shares, a growth of 75.7% from the June 15th total of 6,060,018 shares. Currently, 11.9% of the company's shares are sold short. Based on an